COMPANY

TrAMPoline Pharma

HQ: Aurora, CO source · trampolinepharma.com ↗ · Mountain

Keywords: oncology solid tumor cancer sarcoma

Location: Aurora, CO · source · Oct 14, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $398K (SBIR Phase I 1R43CA310292-01, new, notice Sep 10, 2026). NIH RePORTER 1R43CA310292-01 (Sep 10, 2026)
Evidence (1 event)
- Sep 10, 2026 · NIH RePORTER 1R43CA310292-01
  Organization: TRAMPOLINE PHARMA, INC.; City/State: AURORA, CO; Project number: 1R43CA310292-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 398039; Administering IC: National Cancer Institute; Project title: Development of a Universal Next Generation T Cell Receptor Cancer Therapy: Preclinical Proof-of-Concept and Optimization; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Sep 10, 2026 Grant Government grant — SBIR: $398,039 (annual award, as published), announced Sep 10, 2026. Agency: NIH/NCI. Source: government award database. source ↗

Last 2 years.

Sep 10, 2026 Government grant — SBIR: $398,039 (annual award, as published), announced Sep 10, 2026. Agency: NIH/NCI. Source: government award database. source ↗

Annual award amounts. Total $2.0M.

Aug 15, 2023 NIH award 5R44CA268313-02 FY2023: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI DUKE, RICHARD C; recipient as written: TRAMPOLINE PHARMA, INC., AURORA, CO. Next Generation Autologous TIL Cancer The source ↗
Aug 17, 2022 NIH award 1R44CA268313-01A1 FY2022: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI GONZALEZ, RENE; recipient as written: TRAMPOLINE PHARMA, INC., AURORA, CO. Next Generation Autologous TIL Cancer Th source ↗